Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.
Article Details
- CitationCopy to clipboard
Liu Y, Jeong H, Takahashi H, Drozda K, Patel SR, Shapiro NL, Nutescu EA, Cavallari LH
Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.
Clin Pharmacol Ther. 2012 Apr;91(4):660-5. doi: 10.1038/clpt.2011.269. Epub 2012 Feb 29.
- PubMed ID
- 22378156 [ View in PubMed]
- Abstract
The cytochrome P450 (CYP) 2C9 R150H (*8) allele occurs commonly in African Americans and is associated with lower warfarin dose requirements. We conducted a pharmacokinetic study to examine whether the CYP2C9*8 allele impacts warfarin clearance in African-American patients. We also conducted an in vitro kinetic study of S-warfarin 7-hydroxylation using complementary DNA (cDNA)-expressed CYP2C9 enzymes. We observed a 30% reduction in the unbound oral clearance of S-warfarin and a 25% lower R- to S-warfarin plasma concentration ratio in patients with the CYP2C9*8 allele (n = 12) as compared to CYP2C9*1 homozygotes (n = 26). Consistent with these findings, the in vitro intrinsic clearance of S-warfarin was 30% lower with the cDNA-expressed R150H protein as compared to the wild-type protein. These data show that the R150H variant protein expressed by the CYP2C9*8 allele is associated with lower S-warfarin clearance. This finding provides clinical and experimental evidence to explain the lower warfarin dose requirements in patients with the CYP2C9*8 allele.
DrugBank Data that Cites this Article
- Pharmaco-genomics
Drug Interacting Gene/Enzyme Allele name Genotypes Defining change(s) Type(s) Description Details Phenytoin Cytochrome P450 2C9
Gene symbol: CYP2C9
UniProt: P11712CYP2C9*8 Not Available - 449G>A (rs7900194)
Effect Inferred Poor drug metabolizer, lower dose requirements Details Celecoxib Cytochrome P450 2C9
Gene symbol: CYP2C9
UniProt: P11712CYP2C9*8 Not Available - 449G>A (rs7900194)
Effect Inferred Poor drug metabolizer, lower dose requirements Details Warfarin Cytochrome P450 2C9
Gene symbol: CYP2C9
UniProt: P11712CYP2C9*8 Not Available - 449G>A (rs7900194)
Effect Inferred Poor drug metabolizer, lower dose requirements Details Clopidogrel Cytochrome P450 2C9
Gene symbol: CYP2C9
UniProt: P11712CYP2C9*8 Not Available - 449G>A (rs7900194)
Effect Inferred Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions Details Acetylsalicylic acid Cytochrome P450 2C9
Gene symbol: CYP2C9
UniProt: P11712CYP2C9*8 Not Available - 449G>A (rs7900194)
Effect Inferred Poor drug metabolizer, lower dose requirements Details Glipizide Cytochrome P450 2C9
Gene symbol: CYP2C9
UniProt: P11712CYP2C9*8 Not Available - 449G>A (rs7900194)
Effect Inferred Poor drug metabolizer, lower dose requirements Details Tolbutamide Cytochrome P450 2C9
Gene symbol: CYP2C9
UniProt: P11712CYP2C9*8 Not Available - 449G>A (rs7900194)
Effect Inferred Poor drug metabolizer, lower dose requirements Details Acenocoumarol Cytochrome P450 2C9
Gene symbol: CYP2C9
UniProt: P11712CYP2C9*8 Not Available - 449G>A (rs7900194)
Effect Inferred Poor drug metabolizer, associated with lower dose requirement. Details Phenprocoumon Cytochrome P450 2C9
Gene symbol: CYP2C9
UniProt: P11712CYP2C9*8 Not Available - 449G>A (rs7900194)
ADR Inferred Associated with delayed stabilization. If carrier of rs9934438 as well, increased risk of severe overanticoagulation. Details